Voglibose

Hersteller MedChem Express
Kategorie
Typ Inhibitors
Specific against other
Menge 100mg
ArtNr HY-B0025-100mg
eClass 6.1 30220300
eClass 9.0 32160605
Lieferbar
CAS No.
83480-29-9
Purity
>98%
MW
2672762
Formula
C10H21NO7
Solubility
10 mM in H2O
Biological Description
Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against alpha-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
Target: alpha-glucosidases
glibose can inhibit the intestinal alpha-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].
Menge: 100mg
Lieferbar: In stock
Listenpreis: 161,43 €
Rabatt: -10,0%
Preis: 145,29 €
Sie sparen: 16,14 €
lieferbar

Vergleichen

Angebot anfordern

Fragen zum Produkt?
 
Schließen